%PDF-1.2 % 10 0 obj << /Length 11 0 R >> stream BT 90 709.5 TD 0 0 0 rg /F0 12 Tf 0 Tc 0 Tw ( ) Tj 49.5 -24.75 TD 0 0 0.502 rg /F1 24 Tf -0.0616 Tc 0.0616 Tw (New prostate cancer biomarkers ) Tj -1.5 -27.75 TD 0.0207 Tc -0.0207 Tw (validated by independent studies) Tj 336 0 TD 0 Tc 0 Tw ( ) Tj -384 -16.5 TD 0 0 0 rg /F0 12 Tf ( ) Tj 14.25 -15 TD /F1 14.25 Tf -0.007 Tc 0.1112 Tw (Isabelle Guyon+, Thomas A. Stamey*, Herbert A. Fritsche++, and ) Tj 137.25 -16.5 TD -0.0557 Tc 0.2432 Tw (Stephen D. Barnhill+) Tj 128.25 0 TD /F0 14.25 Tf 0 Tc 0.1875 Tw ( ) Tj 3.75 0 TD ( ) Tj -213.75 -15.75 TD -0.1851 Tc 0.2476 Tw (+ Health Discovery Corporation, Savannah, Georgia ) Tj 296.25 0 TD 0 Tc 0.1875 Tw ( ) Tj -357.75 -16.5 TD -0.1541 Tc 0.2479 Tw (++ University of Texas, M.D. Anderson Cancer Center ) Tj 312.75 0 TD -0.1148 Tc 0.3022 Tw (in Houston, Texas ) Tj 106.5 0 TD 0 Tc 0.1875 Tw ( ) Tj -402 -15.75 TD -0.2156 Tc 0.4031 Tw (* Department of Urology at Stanford University School of Medicine) Tj 380.25 0 TD 0 Tc 0.1875 Tw ( ) Tj -189.75 -21.75 TD ( ) Tj 3.75 0 TD /F2 14.25 Tf -0.2115 Tw ( ) Tj -219.75 -18.75 TD /F1 14.25 Tf -0.2376 Tc 0 Tw (Summary) Tj 58.5 0 TD 0 Tc 0.1875 Tw ( ) Tj -58.5 -15 TD /F0 12 Tf -0.4425 Tc 10.1925 Tw (With our analytical tools we have) Tj 0 Tc 0 Tw ( ) Tj 0 -13.5 TD -0.456 Tc 0.456 Tw (analyzed ) Tj 50.25 0 TD /F1 12 Tf -0.3437 Tc 8.5937 Tw (microarray data) Tj 87.75 0 TD /F0 12 Tf -0.4575 Tc 7.9575 Tw ( with over) Tj 0 Tc 0 Tw ( ) Tj -138 -13.5 TD /F1 12 Tf 0.114 Tc 8.886 Tw (20,000 genes) Tj 74.25 0 TD /F0 12 Tf -0.2527 Tc 8.5027 Tw (. We have discovered) Tj 0 Tc 0 Tw ( ) Tj -74.25 -14.25 TD /F1 12 Tf -0.2083 Tc 7.7083 Tw (molecular patterns characteristic) Tj 0 Tc 0 Tw ( ) Tj 189 0 TD /F0 12 Tf -0.498 Tc -0.252 Tw (of ) Tj -189 -13.5 TD /F1 12 Tf -0.3672 Tc 0.3672 Tw (zonal ) Tj 49.5 0 TD /F0 12 Tf -0.276 Tc 0.276 Tw (and ) Tj 39.75 0 TD /F1 12 Tf -0.1422 Tc 0 Tw (histologic) Tj 47.25 0 TD 0.0308 Tc 20.2192 Tw (al tissue) Tj 0 Tc 0.75 Tw ( ) Tj -136.5 -14.25 TD -0.0536 Tc 0 Tw (classification) Tj 64.5 0 TD /F0 12 Tf -0.2607 Tc 4.0107 Tw ( of the prostate. We have) Tj 0 Tc 0 Tw ( ) Tj -64.5 -13.5 TD -0.5477 Tc 16.2977 Tw (found promising) Tj 0 Tc -0.75 Tw ( ) Tj 105.75 0 TD /F1 12 Tf -0.123 Tc 15.123 Tw (prostate cancer) Tj 0 Tc -0.75 Tw ( ) Tj -105.75 -13.5 TD -0.3828 Tc 0 Tw (biomarkers) Tj 57 0 TD /F0 12 Tf -0.6982 Tc 8.9482 Tw ( yielding) Tj 0 Tc -0.75 Tw ( ) Tj 55.5 0 TD /F1 12 Tf -0.024 Tc 7.524 Tw (90% sensitivity) Tj 0 Tc 0 Tw ( ) Tj -112.5 -14.25 TD -0.1727 Tc 20.4227 Tw (and specificity) Tj 91.5 0 TD /F0 12 Tf -0.444 Tc 20.694 Tw ( on completely) Tj 0 Tc -0.75 Tw ( ) Tj -91.5 -13.5 TD -0.3293 Tc 6.1418 Tw (independently collected data. We have) Tj 0 Tc 0 Tw ( ) Tj 0 -14.25 TD -0.5 Tc 17.75 Tw (also found promising) Tj 0 Tc -0.75 Tw ( ) Tj 147.75 0 TD /F1 12 Tf -0.1758 Tc 0.1758 Tw (diagnostic ) Tj -147.75 -13.5 TD -0.1886 Tc 0.9386 Tw (markers ) Tj 52.5 0 TD /F0 12 Tf -0.526 Tc 0 Tw (and) Tj 16.5 0 TD /F1 12 Tf -0.243 Tc 6.993 Tw ( new drug targets) Tj 0 Tc 0.75 Tw ( ) Tj 116.25 0 TD /F0 12 Tf -0.414 Tc 0.414 Tw (for ) Tj -185.25 -13.5 TD /F1 12 Tf -0.224 Tc 0 Tw (BPH) Tj 24 0 TD /F0 12 Tf 0 Tc (. ) Tj 6 0 TD /F3 14.25 Tf -0.2115 Tw ( ) Tj -30 -18.75 TD /F2 12 Tf -0.336 Tw ( ) Tj 0 -18 TD /F1 14.25 Tf 0.0906 Tc 0.0969 Tw (1 . Background) Tj 94.5 0 TD 0 Tc 0.1875 Tw ( ) Tj -94.5 -14.25 TD /F0 12 Tf 0 Tw ( ) Tj 0 -14.25 TD /F4 12 Tf 0.0221 Tc -0.0221 Tw (Prostate cancer is a deadly disease\205) Tj 183 0 TD 0 Tc 0 Tw ( ) Tj -183 -13.5 TD /F0 12 Tf -0.257 Tc 6.557 Tw (There are an estimated 300,000 new) Tj 0 Tc -0.75 Tw ( ) Tj 0 -13.5 TD -0.1993 Tc 4.5493 Tw (cases and 41,000 deaths from prostate) Tj 0 Tc 0 Tw ( ) Tj 0 -14.25 TD -0.3249 Tc 0.3249 Tw (cancer each year in the US alone.) Tj 151.5 0 TD 0 Tc 0 Tw ( ) Tj 3 0 TD ( ) Tj -154.5 -13.5 TD /F1 12 Tf ( ) Tj 0 -14.25 TD /F4 12 Tf 0.1196 Tc -0.1196 Tw (\205 but most patients do not die of it!) Tj 180 0 TD 0 Tc 0 Tw ( ) Tj -180 -13.5 TD /F0 12 Tf -0.4497 Tc 3.0747 Tw (Clinical studies indicate that 50% of men) Tj 0 Tc -0.75 Tw ( ) Tj 0 -13.5 TD -0.22 Tc 1.22 Tw (over age 50 ) Tj 61.5 0 TD -0.2982 Tc 0.9411 Tw (and 70% of men over age 70 ) Tj -61.5 -14.25 TD -0.2948 Tc 5.9948 Tw (have prostate cancer. However, of all) Tj 0 Tc -0.75 Tw ( ) Tj 0 -13.5 TD -0.332 Tc 9.332 Tw (men diagnosed with prostate cancer) Tj 0 Tc 0 Tw ( ) Tj 0 -14.25 TD -0.5506 Tc 7.1756 Tw (during their lifetimes only 3% die of) Tj 0 Tc -0.75 Tw ( ) Tj 0 -13.5 TD -0.1596 Tc 0.1596 Tw (Prostate Cancer!) Tj 77.25 0 TD 0 Tc 0 Tw ( ) Tj -77.25 -13.5 TD ( ) Tj 234 411.75 TD /F4 12 Tf 0.0053 Tc -0.0053 Tw (The era of PSA is over) Tj 111.75 0 TD 0 Tc 0 Tw ( ) Tj -111.75 -14.25 TD /F0 12 Tf -0.3508 Tc 5.6008 Tw (The standard blood test measuring the) Tj 0 Tc 0 Tw ( ) Tj 0 -13.5 TD -0.3667 Tc 4.8667 Tw (level of prostate specific antigen \(PSA) Tj 194.25 0 TD -0.246 Tc 0.246 Tw (\) ) Tj -194.25 -13.5 TD -0.396 Tc 2.2174 Tw (has recently been shown to reveal mostly ) Tj 0 -14.25 TD -0.3246 Tc 8.0121 Tw (benign prostate hyperplasia \(BPH\), a) Tj 0 Tc 0 Tw ( ) Tj 0 -13.5 TD -0.4826 Tc 8.4326 Tw (condition that is not life threatening,) Tj 0 Tc 0 Tw ( ) Tj 0 -14.25 TD -0.1143 Tc 6.8643 Tw (NOT Prostate Cancer.) Tj 0 Tc 0 Tw ( ) Tj 127.5 0 TD -0.374 Tc 6.374 Tw (Current serum) Tj 0 Tc -0.75 Tw ( ) Tj -127.5 -13.5 TD -0.2411 Tc 6.2411 Tw (PSA based cancer detection strategies) Tj 0 Tc 0 Tw ( ) Tj 0 -13.5 TD -0.4519 Tc 8.5519 Tw (result in an unacceptable, high false) Tj 0 Tc 0 Tw ( ) Tj 0 -14.25 TD -0.3633 Tc 11.3633 Tw (positive rate, this leads) Tj 135 0 TD -0.168 Tc 10.668 Tw ( to) Tj 0 Tc 0 Tw ( ) Tj 36 0 TD /F1 12 Tf -0.417 Tc 0.417 Tw (many ) Tj -171 -13.5 TD -0.0313 Tc 11.2813 Tw (unnecessary biopsies) Tj 0 Tc 0.75 Tw ( ) Tj 130.5 0 TD /F0 12 Tf -0.246 Tc 0 Tw (\() Tj 3.75 0 TD -0.5117 Tc 11.0117 Tw (only \274 of) Tj 0 Tc -0.75 Tw ( ) Tj -134.25 -14.25 TD -0.3229 Tc 7.2604 Tw (biopsies are positive for cancer) Tj 168 0 TD -0.2685 Tc 7.0185 Tw (\) and) Tj 0 Tc 0 Tw ( ) Tj -168 -13.5 TD -0.4645 Tc 11.3395 Tw (result in over) Tj 79.5 0 TD -0.246 Tc 0 Tw (-) Tj 4.5 0 TD -0.3328 Tc 10.8328 Tw (diagnosis of prostate) Tj 0 Tc 0 Tw ( ) Tj -84 -13.5 TD -0.2386 Tc 1.5511 Tw (cancers, which do not need to be treated. ) Tj 0 -14.25 TD -0.3938 Tc 12.0188 Tw (This leads to) Tj 0 Tc 0 Tw ( ) Tj 94.5 0 TD /F1 12 Tf -0.1388 Tc 11.3888 Tw (many unnecessary) Tj 0 Tc 0 Tw ( ) Tj -94.5 -13.5 TD -0.0713 Tc 0.0713 Tw (prostatectomies. ) Tj 90 0 TD /F0 12 Tf -0.3699 Tc 4.6199 Tw (In this contrext, there) Tj 0 Tc 0 Tw ( ) Tj -90 -14.25 TD -0.2652 Tc 3.1402 Tw (is a critical need for a P) Tj 123 0 TD -0.3254 Tc 1.4504 Tw (SA replacement ) Tj -123 -13.5 TD -0.3827 Tc 4.5077 Tw (that can accurately discriminate between) Tj 0 Tc -0.75 Tw ( ) Tj 0 -13.5 TD -0.3414 Tc 16.8414 Tw (latent, non) Tj 63 0 TD -0.246 Tc 0 Tw (-) Tj 4.5 0 TD -0.3309 Tc 16.0809 Tw (aggressive cancer and) Tj 0 Tc 0 Tw ( ) Tj -67.5 -14.25 TD -0.4577 Tc 11.9577 Tw (clinically significant Prostate Cancer.) Tj 198 0 TD 0 Tc 0 Tw ( ) Tj -198 -13.5 TD -0.4205 Tc 3.5455 Tw (The results of our analysis are important) Tj 0 Tc 0 Tw ( ) Tj 0 -14.25 TD -0.216 Tc 0.216 Tw (steps towards that end.) Tj 105 0 TD 0 Tc 0 Tw ( ) Tj -105 -15.75 TD /F5 14.25 Tf -0.2115 Tw ( ) Tj 0 -13.5 TD /F4 12 Tf -0.024 Tc 0.024 Tw (Zones and grades) Tj 87 0 TD 0 Tc 0 Tw ( ) Tj -87 -14.25 TD /F0 12 Tf -0.4458 Tc 6.7458 Tw (The prostate is traditionally though of) Tj 0 Tc -0.75 Tw ( ) Tj 0 -13.5 TD -0.3666 Tc 8.1666 Tw (being composed of three zones: the) Tj 0 Tc 0 Tw ( ) Tj 0 -14.25 TD -0.3525 Tc 8.04 Tw (peripheral zone \(PZ\) has the) Tj 0 Tc 0 Tw ( ) Tj 168.75 0 TD -0.3917 Tc 0.3917 Tw (largest ) Tj -168.75 -13.5 TD -0.2895 Tc 2.5395 Tw (number cancers \(60) Tj 94.5 0 TD -0.246 Tc 0 Tw (-) Tj 4.5 0 TD -0.228 Tc 1.728 Tw (80%\), and the worst ) Tj -99 -13.5 TD -0.388 Tc 0.2809 Tw (prognosis. The central zone CZ has only ) Tj 184.5 0 TD 0 Tc 0 Tw ( ) Tj ET endstream endobj 11 0 obj 8394 endobj 4 0 obj << /Type /Page /Parent 5 0 R /Resources << /Font 20 0 R /ProcSet 2 0 R >> /Contents 10 0 R >> endobj 20 0 obj << /F0 6 0 R /F1 8 0 R /F2 12 0 R /F3 14 0 R /F4 16 0 R /F5 18 0 R >> endobj 22 0 obj << /Length 23 0 R >> stream BT 90 385.5 TD 0 0 0 rg /F0 12 Tf 0 Tc 0 Tw (5) Tj 6 0 TD -0.246 Tc (-) Tj 4.5 0 TD -0.3643 Tc 5.4643 Tw (20% of the cancers. The transitional) Tj 0 Tc -0.75 Tw ( ) Tj -10.5 -13.5 TD -0.4076 Tc 7.0076 Tw (zone \(TZ\) is essentially composed of) Tj 0 Tc -0.75 Tw ( ) Tj 0 -14.25 TD -0.565 Tc 5.065 Tw (tissue growing in the aging) Tj 135 0 TD -0.4785 Tc 4.2285 Tw ( man known) Tj 0 Tc -0.75 Tw ( ) Tj -135 -13.5 TD -0.3124 Tc 4.5124 Tw (as benign prostate hyperplasia or BPH.) Tj 0 Tc 0 Tw ( ) Tj 0 -13.5 TD -0.375 Tc (Only10) Tj 33.75 0 TD -0.246 Tc (-) Tj 4.5 0 TD -0.3214 Tc 2.6785 Tw (18% of the cancers occur in the ) Tj -38.25 -14.25 TD -0.4242 Tc 10.3617 Tw (TZ. Healthy and malignant prostate) Tj 0 Tc 0 Tw ( ) Tj 0 -13.5 TD -0.4135 Tc 3.8635 Tw (tissues can be recognized by histological) Tj 0 Tc -0.75 Tw ( ) Tj 0 -14.25 TD -0.5047 Tc 11.7547 Tw (staining and classified into healthy,) Tj 0 Tc 0 Tw ( ) Tj 0 -13.5 TD -0.2481 Tc 8.6481 Tw (BPH, or cancer. Several grades of) Tj 0 Tc -0.75 Tw ( ) Tj T* -0.2653 Tc 12.0153 Tw (cancers can also ) Tj 11.25 Tc 0 Tw (b) Tj 118.5 0 TD -0.4724 Tc 11.7224 Tw (e distinguished,) Tj 0 Tc 0 Tw ( ) Tj -118.5 -14.25 TD -0.4821 Tc 9.2321 Tw (ranging from 1 to 5. Curability is) Tj 0 Tc 0 Tw ( ) Tj 0 -13.5 TD -0.3856 Tc 2.5285 Tw (inversely related to the fraction of cancer ) Tj 0 -14.25 TD -0.338 Tc 4.6505 Tw (tissue of grade 4 or 5. Dysplasia is a) Tj 0 Tc 0 Tw ( ) Tj 0 -13.5 TD -0.4937 Tc 10.3937 Tw (tissue anomaly thought of being a) Tj 0 Tc 0 Tw ( ) Tj T* -0.2746 Tc 1.9889 Tw (precursor of cancer. Our study takes into ) Tj 0 -14.25 TD -0.2957 Tc 0.2957 Tw (account ) Tj 44.25 0 TD /F1 12 Tf -0.1675 Tc 5.4175 Tw (zonal and histological tissue) Tj 0 Tc 0.75 Tw ( ) Tj -44.25 -13.5 TD 0.024 Tc 0 Tw (classif) Tj 31.5 0 TD -0.1311 Tc (ication) Tj 33 0 TD /F0 12 Tf 0 Tc (.) Tj 3 0 TD ( ) Tj -67.5 -14.25 TD ( ) Tj 0 -15 TD /F1 14.25 Tf -0.0111 Tc 0.1986 Tw (2 . Material and Methods) Tj 155.25 0 TD 0 Tc 0.1875 Tw ( ) Tj -155.25 -15 TD /F0 12 Tf -0.3428 Tc 5.8428 Tw (Three elements are key to success in) Tj 0 Tc -0.75 Tw ( ) Tj 0 -13.5 TD -0.3507 Tc -0.0243 Tw (biomarker discover: ) Tj 93 0 TD 0 Tc 0 Tw ( ) Tj 141 278.25 TD (\226) Tj 6 0 TD ( ) Tj 11.25 0 TD /F1 12 Tf -0.021 Tc (Samples:) Tj 45.75 0 TD /F0 12 Tf -0.4957 Tc 8.1832 Tw ( the availability of good) Tj 0 Tc 0 Tw ( ) Tj -63 -13.5 TD -0.4556 Tc 22.4556 Tw (samples with accurate clinical) Tj 0 Tc -0.75 Tw ( ) Tj 0 -14.25 TD -0.361 Tc 0 Tw (annotations.) Tj 54 0 TD 0 Tc ( ) Tj -54 -13.5 TD (\226) Tj 6 0 TD ( ) Tj 6.75 0 TD /F1 12 Tf 0.0725 Tc (Measurements:) Tj 79.5 0 TD /F0 12 Tf -0.5037 Tc 3.5037 Tw ( a sensitive measuring) Tj 0 Tc -0.75 Tw ( ) Tj -92.25 -13.5 TD -0.3646 Tc 8.6146 Tw (assay, good experimental design and) Tj 0 Tc 0 Tw ( ) Tj 0 -14.25 TD -0.3428 Tc 0.3428 Tw (sample pr) Tj 44.25 0 TD -0.4253 Tc 0 Tw (ocessing.) Tj 41.25 0 TD 0 Tc ( ) Tj -85.5 -13.5 TD (\226) Tj 6 0 TD ( ) Tj 7.5 0 TD /F1 12 Tf -0.01 Tc (Analysis:) Tj 46.5 0 TD /F0 12 Tf -0.3194 Tc 4.6319 Tw ( the use of state) Tj 87.75 0 TD -0.246 Tc 0 Tw (-) Tj 4.5 0 TD -0.123 Tc (of) Tj 9 0 TD -0.246 Tc (-) Tj 4.5 0 TD -0.304 Tc 4.054 Tw (the art) Tj 0 Tc 0 Tw ( ) Tj -165.75 -14.25 TD -0.3702 Tc 0.3702 Tw (analytical biomarker discovery software.) Tj 182.25 0 TD 0 Tc 0 Tw ( ) Tj -182.25 -12.75 TD /F3 11.25 Tf -0.1275 Tw ( ) Tj 0 -13.5 TD /F0 12 Tf -0.416 Tc 3.416 Tw (With our patented analytical tools, which) Tj 0 Tc -0.75 Tw ( ) Tj T* -0.348 Tc 5.598 Tw (have proven to be superior in several) Tj 0 Tc -0.75 Tw ( ) Tj 0 -14.25 TD -0.4789 Tc 6.1789 Tw (studies, we have analyzed high quality) Tj 0 Tc -0.75 Tw ( ) Tj 0 -13.5 TD -0.3478 Tc 20.5978 Tw (microarray data from Stanford) Tj 0 Tc 0 Tw ( ) Tj 0 -14.25 TD -0.4994 Tc 0.4994 Tw (University and ) Tj 67.5 0 TD -0.2229 Tc 0.2229 Tw (other sources. ) Tj 66.75 0 TD 0 Tc 0 Tw ( ) Tj -134.25 -13.5 TD /F4 12 Tf ( ) Tj 0 -13.5 TD 0.0776 Tc -0.2651 Tw (An exceptional and challenging dataset) Tj 198 0 TD 0 Tc 0 Tw ( ) Tj -198 -14.25 TD /F0 12 Tf -0.3081 Tc 4.6206 Tw (We performed our biomarker discovery) Tj 0 Tc -0.75 Tw ( ) Tj 0 -13.5 TD -0.2947 Tc 3.8304 Tw (with a dataset of 87 prostate tissues of) Tj 0 Tc -0.75 Tw ( ) Tj 0 -14.25 TD -0.4178 Tc 6.6053 Tw (different zones and histological grades.) Tj 0 Tc 0 Tw ( ) Tj 0 -13.5 TD -0.3036 Tc 2.6473 Tw (The data, provided by the team of Prof. ) Tj T* -0.3977 Tc 2.7977 Tw (Stamey at Stanford University \(Table ) Tj 185.25 0 TD -0.082 Tc 0.082 Tw (1\), ) Tj -185.25 -14.25 TD -0.4712 Tc 5.7212 Tw (is unique in the sense that it contains) Tj 0 Tc 0 Tw ( ) Tj 0 -13.5 TD -0.3326 Tc 1.3326 Tw (tissues that are ) Tj 73.5 0 TD /F1 12 Tf -0.0076 Tc 1.5076 Tw (laser microdissected) Tj 103.5 0 TD /F0 12 Tf -0.276 Tc 1.026 Tw ( and ) Tj ET 1 1 1 rg 75.75 396 462 42 re f q 82.5 654 30 15.75 re h W n BT 82.5 657.75 TD 0 0 0 rg /F1 14.25 Tf -0.2199 Tc 0 Tw (Zone) Tj ET Q q 132 654 156 15.75 re h W n BT 132 657.75 TD 0 0 0 rg /F1 14.25 Tf 0.0991 Tc 0.0884 Tw (Histological classification) Tj ET Q BT 288 657.75 TD 0 0 0 rg /F0 14.25 Tf 0 Tc 0.1875 Tw ( ) Tj ET q 321 654 29.25 15.75 re h W n BT 321 657.75 TD /F1 14.25 Tf -0.2773 Tc 0 Tw (Num) Tj ET Q BT 350.25 657.75 TD ( ) Tj ET q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 75 652.5 0.75 18 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 75.75 670.5 49.5 0.24 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 124.5 652.5 0.75 18 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 125.25 670.5 189 0.24 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 313.5 652.5 0.75 18 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 314.25 670.5 48.75 0.24 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 363 652.5 0.75 18 re b* Q BT 82.5 639 TD 0.2692 Tc 0 Tw (CZ) Tj 18 0 TD 0 Tc 0.1875 Tw ( ) Tj 31.5 0.75 TD -0.3806 Tc -0.9319 Tw (Normal ) Tj ET q 132 635.25 27 0.75 re h W n BT 132 624 TD -0.3714 Tc 0 Tw (\(NL\)) Tj ET Q q 159 635.25 6.75 0.75 re h W n BT 159 624 TD 0 Tc 0.1875 Tw ( ) Tj ET Q BT 334.5 639 TD 0.375 Tc 0 Tw (9) Tj ET q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 75 634.5 0.75 18 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 75.75 651.75 49.5 0.75 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 124.5 634.5 0.75 18 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 125.25 651.75 189 0.75 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 313.5 634.5 0.75 18 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 314.25 651.75 48.75 0.75 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 363 634.5 0.75 18 re b* Q BT 132 621 TD -0.1714 Tc 0.3589 Tw (Dysplasia \(Dys\)) Tj ET q 221.25 617.25 1.5 15.75 re h W n BT 221.25 621 TD 0 Tc 0.1875 Tw ( ) Tj ET Q BT 334.5 621 TD 0.375 Tc 0 Tw (4) Tj ET q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 75 616.5 0.75 18 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 124.5 616.5 0.75 18 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 125.25 633.75 189 0.75 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 313.5 616.5 0.75 18 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 314.25 633.75 48.75 0.75 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 363 616.5 0.75 18 re b* Q BT 132 603 TD -0.1106 Tc 0.0481 Tw (Grade 4 cancer \(G4\)) Tj 202.5 0 TD 0.375 Tc 0 Tw (1) Tj ET q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 75 597.75 0.75 18.75 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 124.5 597.75 0.75 18.75 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 125.25 615.75 189 0.75 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 313.5 597.75 0.75 18.75 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 314.25 615.75 48.75 0.75 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 363 597.75 0.75 18.75 re b* Q BT 82.5 585 TD 0.3101 Tc (PZ) Tj 16.5 0 TD 0 Tc 0.1875 Tw ( ) Tj 33 0.75 TD -0.3806 Tc -0.9319 Tw (Normal ) Tj ET q 132 580.5 27 0.75 re h W n BT 132 569.25 TD -0.3714 Tc 0 Tw (\(NL\)) Tj ET Q q 159 580.5 6.75 0.75 re h W n BT 159 569.25 TD 0 Tc 0.1875 Tw ( ) Tj ET Q BT 330.75 585 TD -0.375 Tc 0 Tw (13) Tj ET q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 75 579.75 0.75 18 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 75.75 597.75 49.5 0.24 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 124.5 579.75 0.75 18 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 125.25 597.75 189 0.24 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 313.5 579.75 0.75 18 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 314.25 597.75 48.75 0.24 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 363 579.75 0.75 18 re b* Q BT 132 566.25 TD -0.1714 Tc 0.3589 Tw (Dysplasia \(Dys\)) Tj ET q 221.25 562.5 1.5 15.75 re h W n BT 221.25 566.25 TD 0 Tc 0.1875 Tw ( ) Tj ET Q BT 330.75 566.25 TD -0.375 Tc 0 Tw (13) Tj ET q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 75 561.75 0.75 18 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 124.5 561.75 0.75 18 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 125.25 579 189 0.75 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 313.5 561.75 0.75 18 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 314.25 579 48.75 0.75 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 363 561.75 0.75 18 re b* Q BT 132 548.25 TD -0.1106 Tc 0.0481 Tw (Grade 3 cancer \(G3\)) Tj 198.75 0 TD -0.375 Tc 0 Tw (11) Tj ET q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 75 543.75 0.75 18 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 124.5 543.75 0.75 18 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 125.25 561 189 0.75 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 313.5 543.75 0.75 18 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 314.25 561 48.75 0.75 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 363 543.75 0.75 18 re b* Q BT 132 530.25 TD -0.1294 Tc 0.3169 Tw (Grade 4 canc) Tj 75 0 TD -0.2044 Tc -0.3581 Tw (er \(G4\)) Tj 123.75 0 TD -0.375 Tc 0 Tw (18) Tj ET q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 75 525 0.75 18.75 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 124.5 525 0.75 18.75 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 125.25 543 189 0.75 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 313.5 525 0.75 18.75 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 314.25 543 48.75 0.75 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 363 525 0.75 18.75 re b* Q BT 82.5 512.25 TD 0.2932 Tc (TZ) Tj 17.25 0 TD 0 Tc 0.1875 Tw ( ) Tj 32.25 0 TD -0.2201 Tc 0.0326 Tw (Benign Prostate ) Tj ET q 223.5 508.5 0.75 15.75 re h W n BT 223.5 512.25 TD 0 Tc 0.1875 Tw ( ) Tj ET Q BT 132 494.25 TD -0.2539 Tc 0.4414 Tw (Hyperplasia \(BPH\)) Tj ET q 237.75 490.5 1.5 15.75 re h W n BT 237.75 494.25 TD 0 Tc 0.1875 Tw ( ) Tj ET Q BT 330.75 512.25 TD -0.375 Tc 0 Tw (10) Tj ET q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 75 489.75 0.75 35.25 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 75.75 525 49.5 0.24 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 124.5 489.75 0.75 35.25 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 125.25 525 189 0.24 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 313.5 489.75 0.75 35.25 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 314.25 525 48.75 0.24 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 363 489.75 0.75 35.25 re b* Q BT 132 476.25 TD -0.1106 Tc 0.0481 Tw (Grade 4 cancer \(G4\)) Tj 202.5 0 TD 0.375 Tc 0 Tw (8) Tj ET q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 75 471.75 0.75 18 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 124.5 471.75 0.75 18 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 125.25 489 189 0.75 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 313.5 471.75 0.75 18 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 314.25 489 48.75 0.75 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 363 471.75 0.75 18 re b* Q BT 82.5 457.5 TD /F1 14.25 Tf 0.2577 Tc (Total) Tj 33 0 TD /F0 14.25 Tf 0 Tc 0.1875 Tw ( ) Tj ET q 330.75 453.75 13.5 16.5 re h W n BT 330.75 457.5 TD /F1 14.25 Tf 0.375 Tc 0 Tw (87) Tj ET Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 75 452.25 288 0.75 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 75 453 0.75 18.75 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 75.75 471 49.5 0.75 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 124.5 453 0.75 18.75 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 125.25 471 189 0.75 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 313.5 453 0.75 18.75 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 314.25 471 48.75 0.75 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 j 0 0 0 RG 363 452.25 0.75 19.5 re b* Q q 1 0 0 1 -0.0625 -0.0625 cm 0.75 w 1 J 1 j 0 0 0 RG 75.75 453.75 m 75.75 671.25 l S Q q 215.25 712.5 163.5 15.75 re h W n BT 215.25 716.25 TD /F1 14.25 Tf 0.0531 Tc 0.1344 Tw (Table 1: Our latest dataset) Tj ET Q q 378.75 712.5 7.5 15.75 re h W n BT 378.75 716.25 TD /F1 14.25 Tf ( ) Tj ET Q BT 233.25 699 TD /F1 14.25 Tf -0.1452 Tc 0.3327 Tw (\(Stanford University\)) Tj 127.5 0 TD 0 Tc 0.1875 Tw ( ) Tj ET q 96 0 0 -70.5 427.5 588 cm /im1 Do endstream endobj 23 0 obj 14166 endobj 24 0 obj << /Type /XObject /Subtype /Image /Name /im1 /Filter /DCTDecode /Width 128 /Height 94 /BitsPerComponent 8 /ColorSpace /DeviceRGB /Length 25 0 R >> stream Adobe d C + "+6.++(:SRB3BMPef`bb`knuruvh} ^ a !1AQa"q2B#$Rb34rC%Scs5&DTdE£t6UeuF'Vfv7GWgw(8HXhx )9IYiy *:JZjz ? DWBS&I:I$:D$I$I$ui f],qi<-kSLruO6%D[<(z!#s t;s*t74?9_j[Rm"f>(ʩ!k5pG#ljk@$N%II:I$F4phc[K`&q Uw!*6uIIԠ:(>A9$nH(t`Hc)K 3Jd4 `&7 $ : O ˠ>>" ,hڷ$LL/in֒<Ui-k#ȄttHnjq9q q$7&֙$uN,w2WDWDI&sD,emS9J ѼvUqwۺ_[Mۈ\v-TjTN;wukDN!XDč D fmn'+3cHݦW1rk}Z ; ' Clȟ F )۰5\ (;@%]"kh9ѿ]{A.߽:q@: Ì9 xZ`(=ÿ < {ʐ2:)5Áj!'=)94$qZ[<F:Tq'H2 }ʀ{bKDGAO `hQ J @